Stayble Therapeutics announces Dr Daisuke Sakai as new Scientific Advisor
Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company has strengthened its scientific advisory board with Professor Daisuke Sakai, MD, PhD, as new scientific advisor. Dr Sakai will bring experience from the Japanese perspective in the field of treating degenerative disc disease as well as herniated discs. His broad knowledge in the field will strengthen our current scientific advisory board.
Dr Daisuke Sakai is an Associate Professor in the Department of Orthopaedic Surgery at Tokai University School of Medicine in Kanagawa, Japan. Sakai's main clinical interest is the pathology of degenerative spinal disease and treatment of spinal deformities. He is also the head of the Spinal Disc Disease Research Unit, which focuses primarily on the cellular and molecular biology of the spinal disc. The unit also evaluates different types of new treatments, including those based on stem cells. He has led several clinical trials in degenerative disc disease and received the 2014 Research Achievement Award from the Japanese Orthopaedic Association and the 2018 Berton Rahn Research Award from the AO Foundation.
Andreas Gerward, CEO of Stayble, comments:
"We are at a crucial stage in Stayble's development, preparing the Company for a strategic partnership that will take us through the remaining studies, on to the market and ultimately reach millions of patients. Therefore, I am very pleased to present such an experienced and knowledgeable physician and scientific expert as Dr Sakai. His expertise and understanding of our particular disease area will both strengthen our internal knowledge and make us an even more attractive partner. Being able to get a clinical perspective on the Japanese market complements the current advisors who have a primary focus on Europe and the US."
For more information
Andreas Gerward, VD Stayble Therapeutics AB
Phone: +46 730 808 397
E-mail: andreas.gerward@stayble.se
www.staybletherapeutics.se
About Stayble Therapeutics AB
Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble’s vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient’s chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.